Melinta Therapeutics will make five presentations of clinical, in vitro and pharmacokinetic results from studies of Baxdela™ (delafloxacin), an investigational anionic fluoroquinolone, at the ASM Microbe 2017 meeting.

In addition there will be an oral presentation on the potential of RX-P2177, a novel pyrrolocytosine antibiotic developed internally as part of the ESKAPE pathogen program that uses a proprietary ribosome-targeting platform.  RX-P2177 shows promising activity for the treatment of gonorrhea.

ASM Microbe 2017 will take place June 1–5, 2017 in New Orleans, LA.